Cooley advised Mission Therapeutics on a collaboration with AbbVie in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease.
Financial terms were not disclosed. Pursuant to the agreement, both parties will collaborate during the research stage to identify specific DUBs and discover suitable compounds. AbbVie will then have the option to gain exclusive rights to develop and commercialize DUB inhibitors against up to four selected targets. AbbVie will pay Mission an upfront license fee and Mission is also eligible to receive success-based milestone payments and royalty payments for each commercialized product.